ArtemiC™ Boosts Survival by 85% in Severe Viral Inflammatory Model, Study Finds

Independent Validation of ArtemiC™’s Efficacy

Argent BioPharma’s lead immunomodulatory therapy, ArtemiC™, has received a significant boost from an independent in vivo study conducted by the University of South Florida (USF) and AMC Pharma USA. The study, published in August 2025, demonstrated that ArtemiC™ markedly improves survival rates and reduces viral and inflammatory markers in a severe viral inflammatory mouse model mimicking Acute Respiratory Distress Syndrome (ARDS).

The results showed treated mice had up to an 85% survival rate compared to zero survival in untreated controls, a striking indication of ArtemiC™’s potential to mitigate lethal viral infections. This outcome was accompanied by significant reductions in viral load in lung and brain tissues and a dampening of the cytokine storm, a dangerous hyperinflammatory response that drives morbidity in conditions like ARDS.

A Novel Mechanism Without Immune Suppression

ArtemiC™ is a nano-formulated oral therapy designed to modulate key cytokine pathways involved in inflammation without suppressing the immune system. This targeted approach differentiates it from many existing treatments that risk compromising immune defenses. The study’s findings reinforce ArtemiC™’s mechanism of action as a safe immunomodulator that can control inflammation while preserving antiviral immunity.

Importantly, the study was independently designed, funded, and executed by AMC Pharma USA and USF, without Argent BioPharma’s involvement in the scientific or financial aspects. This independence adds credibility to the findings and supports AMC Pharma’s commercial ambitions in the United States and other territories.

Commercial and Regulatory Implications

The positive data come at a critical time as AMC Pharma advances ArtemiC™’s registration efforts in the US and Mexico, aiming to provide an alternative treatment option for patients with viral-induced ARDS and autoimmune inflammatory conditions. The therapy’s safety profile and efficacy in preclinical and early clinical studies position it well for regulatory approval and market adoption, especially among populations hesitant about vaccines.

Argent BioPharma’s CEO Roby Zomer highlighted the significance of these independent results in validating ArtemiC™’s immunological mode of action and its potential to address severe infections without immune suppression. AMC Pharma’s Brent Yessin emphasized the therapy’s alignment with current public health needs and ongoing efforts to secure regulatory support.

Looking Ahead

While these findings are promising, ArtemiC™ remains an unlicensed OTC drug in the US, and further clinical validation is necessary to confirm its efficacy and safety in humans. The study lays a robust foundation for future clinical trials and regulatory submissions, potentially expanding treatment options for viral inflammatory diseases.